For research use only — not for human or veterinary use

Back to compounds
BPC-157 10mg

Peptides

BPC-157

Research classification
Peptides
Lot documentation pending import

Variant / strength

Price

$32.00

Availability

In stock

SKU BNX-BPC157-10MG

1
View lot testing

For laboratory research use only. Not for human or veterinary use.

Lot & quality

Lot-specific analytical documentation

No verified lot documentation is published for this compound yet. Results, laboratories and purity values are never shown without a source record for the exact lot.

View available lot-specific analytical documentation

Enter lot number

Verification connects to the BioNex lot and COA records in a later phase — no results are returned yet

  1. 01

    Lot Number

  2. 02

    COA

  3. 03

    HPLC

  4. 04

    Mass Spectrometry

  5. 05

    Purity

  6. 06

    Laboratory

  7. 07

    Testing Date

  8. 08

    QR Verification

Research snapshot

Verified research records currently indexed by BioNex

BioNex research coverage · Extended Review in Progress
Publication records
121
Registered clinical trials
4
Human observational
1
Preclinical
2
Reviews
32
Years indexed
20052026

Categories are listed separately and must not be added together: publication records and registered trial records are different record types, and a single study may appear in more than one category.

Compound profile

Research overview

Curated research content has not yet been imported for this compound. No generated summary is shown in its place.

Classification

Research areas

  • Extracellular Matrix Research
  • Growth-Factor Signaling

Targets

Mechanisms under investigation

  • Angiogenic and growth-factor pathway modulation (proposed)

    Investigated/proposed mechanism

    Mechanisms proposed for BPC 157 in review literature include modulation of angiogenic and growth-factor signalling in animal models of soft-tissue injury. These remain proposed mechanisms based on preclinical work.

    Source

Evidence

Evidence breakdown

Direct compound evidence

115

Publication records indexed as describing this compound directly.

Related evidence

0

Parent-molecule or fragment literature. Counted separately and never added to direct evidence.

Human research

  • Human observational1

Records describing research in human participants.

Preclinical research

  • Animal2

Animal and laboratory records. Not human evidence.

Review literature

  • Reviews32

Reviews summarise other work rather than reporting new results.

Registered clinical trials

  • Registered trial records4

Registration records a study, not a result. Trials are counted separately from publications.

Scientific identity

Compound identity

Canonical scientific name
BPC 157 (pentadecapeptide body protection compound 157)
Molecular formula
C62H98N16O22
Molecular weight
1419.5 g/mol
CAS number
137525-51-0
Sequence
GEPPPGKPADDAGLV
Sequence length
15 residues
PubChem CID
9941957
UNII
8ED8NXK95P
Research classification
Peptides

Indexed literature describes: Identity data describe the free (non-salt) pentadecapeptide BPC 157 as represented by PubChem CID 9941957.

These records describe the scientific entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.

Scientific data

Compound
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.5 g/mol
CAS number
137525-51-0
Peptide sequence
GEPPPGKPADDAGLV
Research classification
Peptides

Global research

Research records by jurisdiction

Jurisdictions appear only where an indexed record establishes them. Research recorded in one country never implies authorisation in another.

Loading United States records

Published research

Representative recent records

Verified records currently indexed by BioNex

Loading records

Regulatory

Regulatory records by jurisdiction

Regulatory records are held separately from research evidence. Authorisation or regulatory activity in one jurisdiction never implies the same status in another.

  • BPC-157 listed in FDA Category 2: bulk drug substances for compounding that may present significant safety risks

    U.S. Food and Drug Administration (FDA) · FDA bulk drug substances nominated for compounding — Category 2 (substances that may present significant safety risks). Not an approval, not a clinical-trial determination, not a general prohibition, and not an efficacy judgement. · 2026-04-22

    Not an approval determination

    Primary source

Scientific identity records describe the entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.

BioNex Research Intelligence summarizes and organizes scientific literature for research and educational purposes. Inclusion of a publication, clinical trial, or regulatory record does not constitute endorsement, clinical guidance, or evidence of safety or efficacy for human use.